Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) traded up 2.8% during mid-day trading on Friday . The stock traded as high as $3.40 and last traded at $3.35, with a volume of 101,829 shares. The stock had previously closed at $3.26.

Several analysts have recently issued reports on the company. Cowen and Company reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Friday, August 5th. Zacks Investment Research downgraded Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday. Chardan Capital decreased their price target on Dicerna Pharmaceuticals from $4.00 to $3.50 and set a “neutral” rating for the company in a research note on Monday, August 15th. Stifel Nicolaus decreased their price target on Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday, June 30th. Finally, Leerink Swann reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 10th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $11.85.

The firm has a 50-day moving average of $3.36 and a 200-day moving average of $4.20. The firm’s market capitalization is $69.32 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.75) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.84) by $0.09. Equities analysts forecast that Dicerna Pharmaceuticals Inc. will post ($3.17) earnings per share for the current fiscal year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.